Loading
A phase 2 trial in pancreatic cancer, run by Changhai Hospital, now recruiting.
Central-boost Ablative Radiation Therapy for Solid Tumors (CBART) is a phase 2, interventional study registered as NCT06427460 by Changhai Hospital, with a registry enrolment figure of 67 participants, started 2024-05-12 and due to reach its primary completion in 2025-06-30. Interventions recorded: Central-boost ablative dose delivered by stereotactic body radiation therapy. Conditions listed: Pancreatic Cancer. Primary outcome: One-year local control will be determined.. Pancreatic eligibility wording from the registry: "* Pathologically confirmed lung, liver, pancreas or retroperitoneal malignant tumor". Sites: China. No results are recorded here; the registry entry is the source.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.